Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00975520 | Neurotropic Melanoma of the Head and Neck(RTN2) | completed | N/A | 50 | Melanoma and Skin Cancer Trials LimitedOTHER | 3 | Nov 27, 2024 | clinicaltrials |
| NCT02392871 | Radiotherapy & Combi in Metastatic Melanoma(CombiRT) | completed | Phase 1 / Phase 2 | 10 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Nov 27, 2024 |
| clinicaltrials |
| NCT02791594 | Imaging FDG Flare in Melanoma | completed | — | 21 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT05169957 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | completed | Phase 1 | 2 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | invoX Pharma LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03341143 | Fecal Microbiota Transplant (FMT) in Melanoma Patients | completed | Phase 2 | 20 | Zarour, Hassane, MDOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04091217 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04758988 | AI Augmented Training for Skin Specialists(AISC-SS) | completed | N/A | 1,500 | Herlev HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05615883 | Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients(Agility) | completed | N/A | 16 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04039672 | Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma(MELANOPREDICT) | completed | N/A | 10 | Hospices Civils de LyonOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | completed | Phase 2 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 9, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05982600 | Safety and Avoidance of Futile Excisions Through Skin Tele-triage(SAFEST) | completed | — | 5 | Herlev HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03875079 | A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 7 | Oct 3, 2024 | clinicaltrials |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 1 / Phase 2 | 26 | University of Colorado, DenverOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT03430297 | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma(JS001) | completed | Phase 3 | 256 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | completed | Phase 1 / Phase 2 | 24 | Lokon Pharma ABINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04334824 | Hydrochlorothiazide and Risk of Skin Cancer | completed | — | 2,953,748 | Canadian Network for Observational Drug Effect Studies, CNODESOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05810740 | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | completed | Phase 1 | 37 | Pierre Fabre MedicamentINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586580 | Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1(LENVAMEL) | completed | — | 18 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03319693 | Molecular Characterization of Primary Mucosal Melanoma(MELMUQ) | completed | — | 65 | CHU de ReimsOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03538314 | UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma | completed | Phase 1 | 30 | Ultimovacs ASAINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00809588 | Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | completed | Phase 1 | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01256359 | Docetaxel With or Without AZD6244 in Melanoma(DOC-MEK) | completed | Phase 2 | 83 | University of OxfordOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | completed | — | 290 | Natera, Inc.INDUSTRY | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02893774 | Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer(ELCCA-II) | completed | N/A | 314 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05079113 | Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting | completed | — | 73 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01894672 | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05003622 | Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors(OCEANI) | completed | Phase 1 | 3 | Pierre Fabre MedicamentINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06046144 | Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors(Micro3) | completed | — | 161 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT02394132 | Radiotherapy or Imiquimod in Complex Lentigo Maligna(RADICAL) | completed | Phase 3 | 126 | Melanoma and Skin Cancer Trials LimitedOTHER | 3 | Jun 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2024source: clinicaltrials